Myocardial Infarction (Cardiovascular) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Infarction – Drugs In Development, 2021, provides an overview of the Myocardial Infarction (Cardiovascular) pipeline landscape.

Myocardial infarction is the irreversible necrosis of heart muscle secondary to prolonged ischemia. Symptoms include pain, fullness, and/or squeezing sensation of the chest, jaw pain, toothache, headache, shortness of breath, nausea, vomiting, and/or general epigastric discomfort, sweating, heartburn and/or indigestion, arm pain, upper back pain and general malaise (vague feeling of illness).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocardial Infarction – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Myocardial Infarction (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Infarction (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 23, 11, 1, 51, 13 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 2, 18 and 4 molecules, respectively.

Myocardial Infarction (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Infarction (Cardiovascular).

– The pipeline guide reviews pipeline therapeutics for Myocardial Infarction (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Myocardial Infarction (Cardiovascular) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Myocardial Infarction (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Infarction (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Myocardial Infarction (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Myocardial Infarction (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Actinogen Medical Ltd

Angion Biomedica Corp

Animatus Biosciences LLC

Ankasa Regenerative Therapeutics Inc

Aposcience AG

Applied Therapeutics Inc

Aprogen Inc

APT Therapeutics Inc

AptaTargets SL

AstraZeneca Plc

Athera Biotechnologies AB

Athersys Inc

Axolo Pharma Inc

Bayer AG

Bharat Biotech Ltd

BlueRock Therapeutics LLC

Boehringer Ingelheim International GmbH

Brexogen Inc

Cadila Healthcare Ltd

CardioCreate Inc

Cardior Pharmaceuticals GmbH

CeleCor Therapeutics Inc

Celixir Ltd

CellProthera SAS

CFM Pharma Holding BV

Curacle Co Ltd

Cynata Therapeutics Ltd

DeckTherapeutics Inc

Diffusion Pharmaceuticals Inc

Domainex Ltd

Eight Plus One Pharmaceutical Co Ltd

EndoProtech Inc

Ever Supreme Bio Technology Co Ltd

Evotec SE

EyeGene Inc

Faraday Pharmaceuticals Inc

General Regeneratives Shanghai Ltd

Generium

GNT Pharma Co Ltd

GPCR Therapeutics Inc

Hemostemix Inc

Honya Medical Inc

HUYA Bioscience International LLC

Idorsia Pharmaceutical Ltd

iHeart Japan Corp

InCarda Therapeutics Inc

Innolife Co Ltd

Inotrem SA

IPCA Laboratories Ltd

IPS Heart Inc

Kine Sciences

Lee's Pharmaceutical Holdings Ltd

LTT Bio-Pharma Co Ltd

MandalMed Inc

Marizyme Inc

Merck & Co Inc

Mesoblast Ltd

MIFCOR Inc

MimeTech Srl

Mirae Cell Bio Co Ltd

New World Laboratories Inc

Nexel Co Ltd

Novartis AG

NuvOx Pharma LLC

OMEICOS Therapeutics GmbH

Opsona Therapeutics Ltd

OtiTopic Inc

Oxstem Ltd

Pharmahungary Group

Primary Peptides Inc

Qurgen Inc

R-Pharm

Reata Pharmaceuticals Inc

Recardio GmbH

RegeneRx Biopharmaceuticals Inc

ResoTher Pharma ApS

Ribomic Inc

RION Health Inc

Rubicon Biotechnology Inc

Sentan Pharma Inc

Serca Pharmaceuticals AS

Serpin Pharma LLC

Silver Creek Pharmaceuticals Inc

SmartPharm Therapeutics Inc

Sorrento Therapeutics Inc

T&R Biofab Co Ltd

Takeda Pharmaceutical Co Ltd

Thrombolytic Science International LLC

Translational Sciences Inc

Vaxil Bio Therapeutics Ltd

Viridian Therapeutics Inc

XBiotech Inc

Xcelthera INC

Yichang Humanwell Pharmaceutical Co Ltd

Yuyu Pharma Inc

Zensun (Shanghai) Sci & Tech Co Ltd

Zylem Biosciences Inc

Table of Contents

Table of Contents

Introduction

Myocardial Infarction - Overview

Myocardial Infarction - Therapeutics Development

Myocardial Infarction - Therapeutics Assessment

Myocardial Infarction - Companies Involved in Therapeutics Development

Myocardial Infarction - Drug Profiles

Myocardial Infarction - Dormant Projects

Myocardial Infarction - Discontinued Products

Myocardial Infarction - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Myocardial Infarction, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Myocardial Infarction – Pipeline by Actinogen Medical Ltd, 2021

Myocardial Infarction – Pipeline by Angion Biomedica Corp, 2021

Myocardial Infarction – Pipeline by Animatus Biosciences LLC, 2021

Myocardial Infarction – Pipeline by Ankasa Regenerative Therapeutics Inc, 2021

Myocardial Infarction – Pipeline by Aposcience AG, 2021

Myocardial Infarction – Pipeline by Applied Therapeutics Inc, 2021

Myocardial Infarction – Pipeline by Aprogen Inc, 2021

Myocardial Infarction – Pipeline by APT Therapeutics Inc, 2021

Myocardial Infarction – Pipeline by AptaTargets SL, 2021

Myocardial Infarction – Pipeline by AstraZeneca Plc, 2021

Myocardial Infarction – Pipeline by Athera Biotechnologies AB, 2021

Myocardial Infarction – Pipeline by Athersys Inc, 2021

Myocardial Infarction – Pipeline by Axolo Pharma Inc, 2021

Myocardial Infarction – Pipeline by Bayer AG, 2021

Myocardial Infarction – Pipeline by Bharat Biotech Ltd, 2021

Myocardial Infarction – Pipeline by BlueRock Therapeutics LLC, 2021

Myocardial Infarction – Pipeline by Boehringer Ingelheim International GmbH, 2021

Myocardial Infarction – Pipeline by Brexogen Inc, 2021

Myocardial Infarction – Pipeline by Rubicon Biotechnology Inc, 2021

Myocardial Infarction – Pipeline by Sentan Pharma Inc, 2021

Myocardial Infarction – Pipeline by Serca Pharmaceuticals AS, 2021

Myocardial Infarction – Pipeline by Serpin Pharma LLC, 2021

Myocardial Infarction – Pipeline by Silver Creek Pharmaceuticals Inc, 2021

Myocardial Infarction – Pipeline by SmartPharm Therapeutics Inc, 2021

Myocardial Infarction – Pipeline by Sorrento Therapeutics Inc, 2021

Myocardial Infarction – Pipeline by T&R Biofab Co Ltd, 2021

Myocardial Infarction – Pipeline by Takeda Pharmaceutical Co Ltd, 2021

Myocardial Infarction – Pipeline by Thrombolytic Science International LLC, 2021

Myocardial Infarction – Pipeline by Translational Sciences Inc, 2021

Myocardial Infarction – Pipeline by Vaxil Bio Therapeutics Ltd, 2021

Myocardial Infarction – Pipeline by Viridian Therapeutics Inc, 2021

Myocardial Infarction – Pipeline by XBiotech Inc, 2021

Myocardial Infarction – Pipeline by Xcelthera INC, 2021

Myocardial Infarction – Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, 2021

Myocardial Infarction – Pipeline by Yuyu Pharma Inc, 2021

Myocardial Infarction – Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, 2021

Myocardial Infarction – Pipeline by Zylem Biosciences Inc, 2021

Myocardial Infarction – Dormant Projects, 2021

Myocardial Infarction – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Myocardial Infarction, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports